# MRD-directed Therapy for Low-risk and Intermediate-risk AML.

> **NCT02870777** · PHASE2,PHASE3 · COMPLETED · sponsor: **Nanfang Hospital, Southern Medical University** · enrollment: 743 (actual)

## Conditions studied

- Acute Myeloid Leukemia
- Minimal Residual Disease

## Interventions

- **COMBINATION_PRODUCT:** MRD-directed therapy

## Key facts

- **NCT ID:** NCT02870777
- **Lead sponsor:** Nanfang Hospital, Southern Medical University
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-08
- **Primary completion:** 2019-08-31
- **Final completion:** 2019-12-31
- **Target enrollment:** 743 (ACTUAL)
- **Last updated:** 2020-03-04

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02870777

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02870777, "MRD-directed Therapy for Low-risk and Intermediate-risk AML.". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT02870777. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*